XPhyto Therapeutics Corp
VANCOUVER, CANADA, and UTTENWEILER, GERMANY / ACCESSWIRE / January 13, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTC:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to announce that it has signed a distribution agreement (the "Agreement") with TechUnit s.r.o. (Limited) ("TechUnit") for the distribution of Covid-ID Lab in the Czech Republic as an initial priority market followed by Hungary, Slovakia, Ukraine and Russia.
Covid-ID Lab is a rapid RT-PCR test for the qualitative detection of SARS-CoV-2 based on the reverse transcriptase polymerase chain reaction (RT-PCR) method. To perform the test, Covid-ID Lab requires only a 20-minute PCR run time without prior RNA extraction as part of the sample preparation. After the RT-PCR sample processing, the SARS-CoV-2 virus is detected on a test chip within 5 minutes and if SARS-CoV-2 is present, the result can be read visually immediately.
The Agreement provides TechUnit with the right to distribute and sub-distribute Covid-ID Lab on a non-exclusive basis within the Czech Republic with the potential for territorial exclusivity based on performance. XPhyto looks forward to building a close strategic relationship with TechUnit and will provide its new distributor with technical training and product, strategy, and marketing support. The parties are reviewing opportunities for the distribution of Covid-ID Lab in additional European territories including Hungary, Slovakia, Ukraine, and Russia. TechUnit is a privately owned company based in the Czech Republic focused on medical product distribution, advertisement and promotion.
"Execution of the distribution agreement with TechUnit is an important step toward building strong European sales," said Prof. Dr. Thomas Beckert. "This is an important relationship with excellent potential for additional territorial expansion."
The Company expects to continue to sign additional distribution agreements in the near future and will release details upon execution of such agreements.
XPhyto's diagnostics and drug formulation business is led by Prof. Dr. Beckert. Prof Dr. Beckert is a German-based scientist and corporate executive with over 20 years of healthcare management experience.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.
About XPhyto Therapeutics Corp.
XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
XPhyto Therapeutics Corp.
Hugh Rogers, CEO and Director
Investor Inquiries:
Mr. Knox Henderson
T: 604-551-2360
E: info@xphyto.com
Forward looking statements
This news release includes statements containing forward-looking information within the meaning of applicable Canadian securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "develop", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "potential", "propose" and other similar words, or statements that certain events or conditions "may" or "will" occur, and in this release include the statement regarding the Company's goal of building a successful diagnostic, drug delivery, and medical cannabis company. Forward-looking statements are only predictions based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements, including: that the Company may not succeed in developing a commercial product; that the sale of products may not be a viable business; that the Company may be unable to scale its business; product liability risks; product regulatory risk; general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; currency risks; competition; international risks; and other risks beyond the Company's control. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this news release.
SOURCE: XPhyto Therapeutics Corp
View source version on accesswire.com:
https://www.accesswire.com/683332/XPhyto-signs-Distribution-Agreement-for-Czech-Republic-rollout-planned-for-Hungary-Slovakia-Ukraine-and-Russia
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
EESystem Triumphs Again: Courts Deem Jason Shurka's Claims “Baseless” and “Futile”31.10.2025 14:25:00 CET | Press release
Judges Continue to Side with Energy Enhancement System as Jason Shurka's Legal Maneuvers Collapse LAS VEGAS, NV / ACCESS Newswire / October 31, 2025 /Energy Enhancement System, LLC ("EES") has achieved another decisive victory in its ongoing effort to defend truth, innovation, and integrity against baseless attacks from Jason Shurka and The Light System, Inc. ("TLS"). The United States District Court for the Eastern District of New York has formally granted EES permission to move forward with its full motion to dismiss - a strong indication that the court recognizes the legal and factual strength of EES's position. Judges in multiple jurisdictions have now described Shurka's filings as "baseless" and "futile," repeatedly returning the cases to the very courts where EES first initiated them - and where EES continues to win. Truth Over Deception The latest decision follows months of extensive filings exposing what EES alleges was a coordinated campaign of misinformation and brand confusi
TruMerit's Peter Preziosi Elected President of the Conference of NGOs in Consultative Relationship With the United Nations30.10.2025 21:00:00 CET | Press release
NEW YORK CITY, NEW YORK / ACCESS Newswire / October 30, 2025 / TruMerit President and CEO Peter Preziosi has been elected President of the Conference of Non-Governmental Organizations in Consultative Relationship with the United Nations, also known as CoNGO. CoNGO | TruMerit Conference of Non-Governmental Organizations in Consultative Relationship with the United Nations, also known as CoNGO and TruMerit CoNGO is an international non-governmental organization founded in 1948 that relates to the United Nations through its General Consultative Status granted by the United Nations Economic and Social Council (ECOSOC). It has 525 member organizations from around the world and 106 associate members. Dr. Preziosi was elected to serve for the 2025-29 term this week at the 28th CoNGO General Assembly, which took place in New York with the virtual participation of organizations from around the world. He succeeds the Rev. Dr. Liberato C. Bautista, the main representative to the UN for the Genera
Polaris Renewable Energy Announces Q3 2025 Results30.10.2025 12:50:00 CET | Press release
TORONTO, ONTARIO / ACCESS Newswire / October 30, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to report its financial and operating results for the nine and three months ended September 30, 2025. This earnings release should be read in conjunction with the Company's condensed consolidated interim financial statements and management's discussion and analysis, which are available on the Company's website at www.PolarisREI.com and have been posted on SEDAR+ at www.sedarplus.ca. The dollar figures below are denominated in US Dollars unless noted otherwise. 2025 HIGHLIGHTS Third quarter consolidated energy production totaled 181,235 MWh, representing a 7% increase compared to 168,639 MWh in the same quarter last year. The increase is mainly attributable to the contribution from the Puerto Rican wind farm, acquired on March 3, 2025, which was not part of the portfolio in the comparative quarter of 2024, as well as stronger hydrologi
Polaris Renewable Energy Declares Quarterly Dividend30.10.2025 12:50:00 CET | Press release
TORONTO, ONTARIO / ACCESS Newswire / October 30, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to announce that its board of directors has declared a quarterly dividend of US$0.15 per common share outstanding. This dividend will be paid on November 21st to shareholders of record at the close of business on November 10th. The dividend is an "eligible dividend" as designated for Canadian federal, provincial, and territorial income tax purposes. The board of directors of Polaris Renewable Energy remains committed to paying a quarterly dividend and will evaluate further dividend increases, as appropriate, going forward. About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America & the Caribbean. We are a high-performing and financially sound contributor to the energy transition. The Compan
Camino and Nittetsu Commence Proprietary Leaching Studies for Growth Opportunities at the Puquios Copper Project in Chile30.10.2025 11:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / October 30, 2025 / :Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF) ("Camino" or the "Company") is pleased to announce that its joint venture with Nittetsu Mining Co., Ltd. ("Nittetsu") will initiate leaching studies at Nittetsu's metallurgical and chemical facility in Tokyo. These studies aim to assess the scalability of the Puquios Copper Project ("Puquios"or the "Project"). The Puquios mine is planned as a conventional sulphide leaching operation utilizing solvent extraction and electro winning ("SXEW") technology. All permits required for commencement of construction are in place, with mine construction anticipated in the first half of 2026. To support development, Camino and Nittetsu are actively pursuing a debt facility with a Japanese lender that is expected to offer highly competitive terms in the current mining finance environment. The first stage of the Puquios copper mine development is now on a path towards production. The Company is ev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom